Skip to content

Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients

Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01990495
Acronym
PERFECT
Enrollment
37
Registered
2013-11-21
Start date
2013-11-01
Completion date
2019-09-30
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

Renal failure, Exercise testing, Exercise training, Protein signaling, Skeletal muscle

Brief summary

The majority of individuals with advanced ESRD have reduced exercise capacity in part due to decreased muscle mass. This leads to a reduced ability to perform daily activities, a greater incidence of falls, and a reduced quality of life. The mechanisms responsible for the loss of muscle mass in ESRD are not understood very well. This study is designed to determine the effectiveness of an exercise program on improving muscle mass, exercise capacity and quality of life in persons with ESRD. In addition, the study will attempt to better understand why muscle loss occurs in people with ESRD, the influence exercise has on these mechanisms, and whether the response to exercise can be enhanced with nutrient supplementation.

Detailed description

Elderly patients comprising half the end-stage renal disease (ESRD) population, are especially vulnerable to loss of muscle mass, strength and function, changes that lead to frailty and increased morbidity and mortality. Many factors contribute to the decline in muscle mass and function in the elderly uremic and apart from aging and co-morbid conditions, wasting is worsened by inactivity. Studies in maintenance hemodialysis (MHD) patients have shown that exercise (EX), including endurance, resistance or combined, can counteract the loss of muscle mass and function. However most studies have not specifically targeted the elderly, involved small numbers or lacked controls and the impact on long-term outcome is unknown. Nevertheless, despite substantial evidence indicating that EX is beneficial and low cost, EX is not part of the routine care of MHD patients. In contrast EX is regarded as standard of care for the wasted elderly and also cardiac patients. Some protection against uremic muscle wasting can also be afforded by an adequate protein-calorie intake. Amino acids (AA) from this source serve as substrates for protein synthesis (PS) and also directly activate the mTOR signaling pathway stimulating PS. In normal subjects if AA are ingested at the time of resistance EX, anabolic signaling and PS is enhanced and this leads to increases in muscle mass. Whether the EX and AA stimulated signaling response is intact in elderly MHD patients is unknown and there is little information about the cellular processes invoked. Taking this all together, the investigators plan to test the hypothesis that a home-based EX program, effective in cardiac patients, will improve cardiopulmonary function and muscle mass and function in elderly MHD patients. Also, in a pilot study the investigators will examine whether a protein supplement acutely enhances EX stimulated anabolic signaling. Functionally impaired MHD subjects aged 65-80 yrs are randomized into 2 groups of 30 each, one undergoing EX and the other usual care. After 3 months, half in each group receive a one-time protein-calorie supplement or placebo during an acute bout of EX and muscle biopsied for examining the signaling response. Assays at baseline and at 3 months include cardiopulmonary function, muscle strength and function, body composition by DEXA, thigh muscle volume and composition by CT, quality of life (QOL) and cognitive function, and nutritional, inflammatory, lipid and biochemical status and morphologic and molecular analysis of biopsied muscle. The investigators anticipate that home-based EX will counteract muscle wasting, enhance cardiopulmonary and muscle function and QOL, and reduce surrogate markers of long-term outcome. New insights into the mechanisms whereby EX and nutrients induce an anabolic response in muscle of elderly uremics will be provided and may serve as a basis for devising strategies to counteract loss of muscle mass and function. Finally, the investigators anticipate that the EX program will be user friendly and may thus form a part of the routine care of elderly and perhaps younger MHD patients. If short-term benefits are evident from this study in elderly MHD patients, it could form the basis for a comprehensive long-term outcomes study.

Interventions

OTHERExercise training

Subjects will participate in a center-based and home exercise training program for 3 months.

OTHERUsual Care

This group will serve as control subjects. They will receive only usual clinical care.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Males and females aged 55-80 years undergoing maintenance hemodialysis (MHD) for at least three months and without other active/uncontrolled disease will be studied. * Exercise and usual care groups will be matched by age, body mass index (BMI), MHD duration, and protein intake using a stratified randomization approach. * Subjects will be required to be in the peak VO2 range of 10 to 20 ml/kg/min, equivalent to moderate functional impairment in patients with heart failure. * Subjects will be required to have dialysis treatment for \>3 months with an average Kt/V 1.2, and be able to perform exercise safely.

Exclusion criteria

* Current activity \> 2 hrs/wk of moderate intensity exercise, temporary vascular access, uncontrolled diabetes mellitus, active vasculitis, active autoimmune disease, malignancy, severe obesity (BMI \> 35), alcoholism or other recreational drug use, unstable cardiac disease (abnormal exercise test, angina, uncontrolled arrhythmias or myocardial infarction within three months), peripheral vascular disease (claudication with exercise), lung, liver or intestinal disease, those who are medically unstable and subjects who have received anabolic, catabolic or cytotoxic medications in the past 3 months. * The investigators will also exclude subjects with excessive previous exposure to radiation.

Design outcomes

Primary

MeasureTime frameDescription
Maximal Oxygen Uptake3 monthsThe overall primary outcome for the study is maximal oxygen uptake. Maximal oxygen uptake is the amount of oxygen consumed by the body during maximal exercise. It is the gold standard expression for exercise capacity.

Secondary

MeasureTime frameDescription
Biopsy of the Quadriceps Muscle.3 MonthsThe biopsy procedures will permit the measurement of the percentage of type 1 fibers in the quadriceps muscle. The biopsy procedures will also be used to quantify protein signaling, a measure of the capacity of the muscle to gain or lose muscle mass.
Quality of Life Score3 monthsDisease-specific quality of life instrument is used to quantify broad quality of life domains, including physical function. Higher scores mean better values using a 0-100 scale.

Countries

United States

Participant flow

Participants by arm

ArmCount
Exercise
Subjects will participate in a center-based and home exercise training program for 3 months.
13
Usual Care
This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
15
Total28

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision54

Baseline characteristics

CharacteristicExerciseUsual CareTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
10 Participants13 Participants23 Participants
Age, Categorical
Between 18 and 65 years
3 Participants2 Participants5 Participants
Age, Continuous66.3 years
STANDARD_DEVIATION 7.6
66.2 years
STANDARD_DEVIATION 6.7
66.3 years
STANDARD_DEVIATION 6.9
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants15 Participants28 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Region of Enrollment
United States
13 Participants15 Participants28 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
13 Participants15 Participants28 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 130 / 15
other
Total, other adverse events
0 / 130 / 15
serious
Total, serious adverse events
0 / 130 / 15

Outcome results

Primary

Maximal Oxygen Uptake

The overall primary outcome for the study is maximal oxygen uptake. Maximal oxygen uptake is the amount of oxygen consumed by the body during maximal exercise. It is the gold standard expression for exercise capacity.

Time frame: 3 months

Population: Chronic kidney disease

ArmMeasureValue (MEAN)Dispersion
ExerciseMaximal Oxygen Uptake14.5 ml/kg/minStandard Deviation 3.3
Usual CareMaximal Oxygen Uptake15.1 ml/kg/minStandard Deviation 3.3
Secondary

Biopsy of the Quadriceps Muscle.

The biopsy procedures will permit the measurement of the percentage of type 1 fibers in the quadriceps muscle. The biopsy procedures will also be used to quantify protein signaling, a measure of the capacity of the muscle to gain or lose muscle mass.

Time frame: 3 Months

Population: Maintenance hemodialysis (\>3 months)

ArmMeasureValue (MEAN)Dispersion
ExerciseBiopsy of the Quadriceps Muscle.33.2 Percentage of type 1 fibersStandard Deviation 11
Usual CareBiopsy of the Quadriceps Muscle.30.0 Percentage of type 1 fibersStandard Deviation 9
Secondary

Quality of Life Score

Disease-specific quality of life instrument is used to quantify broad quality of life domains, including physical function. Higher scores mean better values using a 0-100 scale.

Time frame: 3 months

Population: Chronic kidney disease on maintenance hemodialysis.

ArmMeasureValue (MEAN)Dispersion
ExerciseQuality of Life Score48.7 score on a scaleStandard Deviation 25.6
Usual CareQuality of Life Score60.0 score on a scaleStandard Deviation 22.3

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026